The Decade of Neuroscience? – Opportunities & Caveats for Investors
Key Takeaways
Drug development in neurology is challenging due to our limited disease understanding and large, long, costly clinical development, which has led to several painful late-stage failures in the industry resulting in withdrawal of big pharma in the past
Technical advances enable research to fill existing knowledge gaps and regulatory agencies are increasingly supporting novel, alternative clinical trial designs resulting in potentially decreasing burdens for drug developers in that space
VC interest in the neuroscience space is picking up and currently ranks second after the dominating Oncology space in terms of investment rounds and volumes.
Investors may profit from the recent advances in the field as more innovative approaches driven by biotech and shortened clinical development timelines may open up attractive investment options
